Press Releases Johnson & Johnson

Equities

JNJ

US4781601046

Market Closed - Nyse Other stock markets 21:00:02 01/05/2024 BST			5-day change	1st Jan Change
151.2 ^USD	+4.56%		+1.78%	-3.55%

05-01	Sector Update: Health Care Stocks Rise Late Afternoon	MT
05-01	Stocks rise after Fed rate decision, Powell press conference	RE

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

J&J subsidiary proposes paying about $6.48B over 25 years to settle talc ovarian cancer lawsuits	05-01	AQ
Johnson & Johnson Announces Plan by its Subsidiary, LLT Management LLC, to Resolve All Current and Future Ovarian Cancer Talc Claims Through a Consensual “Prepackaged” Reorganization	05-01	BU
Alvotech And Teva's Selarsdi™ (ustekinumab-aekn), Biosimilar To Stelara® Approved By FDA	05-01	AQ
Johnson & Johnson : receives positive CHMP opinion for RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations	04-26	PU
FDA Approval Of Alvotech/Teva Ustekinumab Biosimilar	04-26	AQ
Welfare Plan Class Action Litigation Underscores Importance Of Minding Your Fiduciary Duties	04-24	AQ
Johnson & Johnson to participate in the Bernstein's 40th Annual Strategic Decisions Conference	04-23	AQ
Janssen - CARVYKTI is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy	04-23	AQ
Johnson & Johnson to Participate in the Bernstein’s 40th Annual Strategic Decisions Conference (SDC)	04-22	BU
Johnson & Johnson : CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy	04-22	PU
Johnson & Johnson : First Quarter 2024 2024 First-Quarter Earnings Transcript	04-18	PU
Johnson & Johnson Reports Q1 2024 Results	04-17	AQ
Johnson & Johnson Announces 62nd Consecutive Year of Dividend Increase, Raises Quarterly Dividend by 4.2%	04-17	AQ
Why Establish A Fiduciary Committee For Welfare Benefit Plans?	04-16	AQ
Benylin Paediatric Syrup Banned	04-16	AQ
Zimbabwe Issues Recall On Benylin Paediatric Syrup	04-16	AQ
Johnson & Johnson : First Quarter 2024 1Q24 Other Financial Disclosures	04-16	PU
Johnson & Johnson : 2024 First-Quarter Press Release & Supplemental Schedules	04-16	PU
Johnson & Johnson Announces 62nd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.2%	04-16	BU
CORRECTING and REPLACING Johnson & Johnson Reports Q1 2024 Results	04-16	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 05:30 pm